Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-935 in Developmental and/or Epileptic Encephalopathies
NCT03166215Phase 2Completed
- Sponsor
- Takeda
- Start
- Aug 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of soticlestat in developmental and epileptic encephalopathy (DEE) (3 arms), sponsored by Takeda. Primary endpoint: Percentage of Participants With at Least One Treatment-Emergent Adverse Event up to 120 days. Started Aug 2017; status: completed.
02
Drugs
soticlestat
03
Conditions
developmental and epileptic encephalopathy (DEE)
Beyond the preview
Go deeper on NCT03166215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03166215.